Trevi therapeutics, inc.TRVI.US Overview

US StockHealthcare

(No presentation for TRVI)

Overview AI Analysis AI Earnings Summary Financials Financial Forecast Stock Sentimental Institutions TradingView Chart

TRVI Overall Performance

TRVI AI Analysis & Strategy

TRVI Recent Performance

1.42%

Trevi therapeutics, inc.

0.81%

Avg of Sector

-1.14%

S&P500

TRVI PowerScanner

TRVI Key Information

TRVI Valuation Metrics

TRVI Earnings Table

TRVI Profile

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.